Business
Kura Oncology Reports Second Quarter 2020 Financial Results
– Anticipate preliminary data presentation of menin inhibitor program, KO-539, at ASH – – Continued progress in registration-directed trial of tipifarnib in
About this update from Kura Oncology, Inc.
[{"type":"text","content":"– Anticipate preliminary data presentation of menin inhibitor program, KO-539, at ASH –\n – Continued progress in registration-directed trial of tipifarnib in HRAS mutant HNSCC – – Opportunity to expand to HRAS and PI3K dependent tumors with potential to target up to 50% of HNSCC – – $338.9 million in cash, cash equivalents and investments provide runway into 2023 – – Management to host webcast and conference call today at 4:30 p.m. ET – SAN DIEGO, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today reported second quarter 2020 financial results and provided a corporate update. “Last quarter we implemented a number of strategic measures to focus on our two major development pillars: tipifarnib in HRAS-dependent head and neck squamous cell carcinoma (HNSCC) and KO-539 in acute myeloid leukemia (AML),” said Troy Wilson, Ph.D., J.D., President and Chief Executive Officer of Kura Oncology. “We believe tipifarnib and KO-539 provide opportunities to address large proportions of head and neck cancers and acute leukemias, respectively. Now, following a successful public offering this past quarter, we are well-positioned to advance each of these programs toward important upcoming catalysts.” Corporate Update Encouraging progress in Phase 1/2A trial of menin inhibitor, KO-539 – KO-539 is a potent and small molecule inhibitor of the menin-KMT2A(MLL) protein-protein interaction, with the potential to target at least 35% of patients with AML. A Phase 1/2A clinical trial of KO-539 in patients with relapsed/refractory AML (KOMET-001) continues in dose escalation. Kura remains focused on its goal of reaching a recommended Phase 2 dose and schedule, after which it intends to open expansion cohorts in NPM1-mutant and KMT2A(MLL)-rearranged AML – selected patient populations where KO‑539 has the potential to demonstrate increased clinical benefit. The Company intends to submit an abstract for preliminary data presentation of the KO-539 program at the American Society of Hematology Annual Meeting in December 2020, and continues to add clinical sites to the trial in anticipation of moving into the expansion cohorts. Updated data from Phase 2 trial of tipifarnib in HRAS mutant HNSCC – Kura reported u...